Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stool DNA Analysis Tracks Disease Activity in IBD

By LabMedica International staff writers
Posted on 11 May 2026

Inflammatory bowel disease (IBD) affects an estimated 6–8 million people worldwide and is commonly monitored through colonoscopy and stool testing. More...

Because disease activity can fluctuate, laboratories need noninvasive markers that reflect intestinal inflammation in real time. Human DNA in feces has traditionally been treated as background rather than a measurable analyte. New findings show that cell-of-origin analysis of fecal human DNA can help index disease activity in both pediatric and adult IBD.

Researchers at the Hebrew University of Jerusalem, with Shaare Zedek Medical Center, outline a stool-based approach that profiles human DNA fragments using methylation to determine their cellular origin. The analysis shows that DNA derived from neutrophils dominates the human signal in stool from patients with IBD, rather than colon epithelial DNA as previously assumed. By explicitly measuring host DNA alongside microbial features, the method provides a composite view of gut inflammation.

The study, published in Microbiome, examined pediatric patients in Israel and adult patients in the Netherlands, demonstrating consistent results across ages. Neutrophil DNA levels in stool correlated with established clinical markers, including fecal calprotectin. The authors also introduce a Neutrophil-to-Epithelial Ratio (NER), which more effectively distinguishes remission from active disease than assessing either component alone.

In addition to correlation with current markers, combining human DNA signals with microbiome data enabled machine learning models to predict IBD and differentiate Crohn’s disease from ulcerative colitis. The investigators note that calprotectin assays have detection limits that can hinder assessment in the most severe cases, whereas host DNA profiling captures real-time immune activity. Collectively, the findings suggest a path toward noninvasive, longitudinal monitoring of disease flares and treatment response using a simple stool sample.

“For too long, the human DNA found in stool samples was treated as biological ‘noise’ that we filtered out to focus on microbial data,” said Prof. Moran Yassour, from Hebrew University.

“Our findings show that this DNA contains valuable, unappreciated information, reflecting the immune system’s activity in real time. By analyzing both the human and microbial components together, we can gain a much clearer picture of what is happening in the gut.”

Related Links
Hebrew University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.